Adynxx, Inc. (ADYX) Research

Adynxx, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating and commercializing novel transcription factor decoy technologies to combat pain and inflammatory conditions. Central to its efforts is the AYX platform of transcription factor decoys, which includes brivoligide, currently progressing through Phase II clinical development for reducing post-surgical discomfort. Additionally, AYX2 is a pre-clinical candidate being explored for its potential in treating localized chronic pain. Established in 2007, the company's corporate headquarters are situated in San Francisco, California.

Market snapshot

Symbol
ADYX
Price
$0.00
Day change
0.00%
Market cap
$581.0
P/E ratio
-0.00x
52-week range
0.0001-0.0002
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • BG Medicine, Inc. (BGMD)
  • BIMI International Medical Inc. (BIMI)
  • Bionik Laboratories Corp. (BNKL)
  • ContraFect Corporation (CFRXQ)
  • eFFECTOR Therapeutics, Inc. (EFTR)
  • FusionPharm, Inc. (FSPM)
  • IMV Inc. (IMVIF)
  • Millennium Sustainable Ventures Corp. (MILC)

Recent insider activity

  • FLESHER GREGORY J. — trade (0 shares) on 2019-07-22
  • GONZALEZ DINA — trade (26358 shares) on 2019-05-29
  • GONZALEZ DINA — trade (1577 shares) on 2019-05-29
  • GONZALEZ DINA — trade (1577 shares) on 2019-05-29
  • TPG Group Holdings (SBS) Advisors, Inc. — trade (0 shares) on 2019-05-03

Open Adynxx, Inc. (ADYX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.